Thoracic Surgery Division, Ohio State University Wexner Medical Center, Columbus, Ohio.
Center for Biostatistics, Department of Biomedical Informatics, College of Medicine, Ohio State University, Columbus, Ohio.
Ann Thorac Surg. 2021 Jan;111(1):261-268. doi: 10.1016/j.athoracsur.2020.05.051. Epub 2020 Jun 29.
Early-stage non-small cell lung cancer (NSCLC) is potentially curable with surgical resection. The overall survival rate for early-stage NSCLC may be determined by the healthcare facility type where patients receive their lung cancer treatment.
A total of 103,748 cases with the American Joint Committee on Cancer clinical stage I and II NSCLC that were reported to the National Cancer Database at over 1150 facilities were analyzed in this study. Healthcare facilities were dichotomized into the community and academic facility types. Marginal multivariable Cox proportional hazards models were used to evaluate differences in overall survival. Propensity score methodology with inverse probability of treatment weighting was used to adjust for facility volume and patient-related baseline differences between facility types.
Patients with early-stage NSCLC who were treated at academic facility types had a significantly better median overall survival (63.2 months) compared with patients who received care at community healthcare facilities (54.2 months) (hazard ratio, 0.86; 95% confidence interval, 0.82-0.91; P < .0001). The surgical quality outcomes for NSCLC surgery, including 30-day mortality, 90-day mortality, and the median number of lymph nodes removed were significantly better for patients treated at the academic facility types.
Patients with early-stage NSCLC who were treated at academic facility types had a significantly higher overall median survival compared with patients treated at community facility types. The short-term surgical quality outcomes were significantly better for patients who underwent surgery for early-stage NSCLC at academic facility types.
早期非小细胞肺癌(NSCLC)通过手术切除有治愈的可能。早期 NSCLC 的总生存率可能取决于患者接受肺癌治疗的医疗机构类型。
本研究共分析了 103748 例美国癌症联合委员会临床分期 I 和 II 期 NSCLC 患者,这些患者在 1150 多家医疗机构向国家癌症数据库报告。医疗机构分为社区和学术机构类型。边缘多变量 Cox 比例风险模型用于评估总生存率的差异。采用倾向性评分方法,采用逆概率治疗加权法调整设施数量和设施类型之间患者相关的基线差异。
与在社区医疗机构接受治疗的患者相比(54.2 个月),在学术医疗机构类型接受治疗的早期 NSCLC 患者的中位总生存期(63.2 个月)显著延长(风险比,0.86;95%置信区间,0.82-0.91;P<0.0001)。NSCLC 手术的手术质量结果,包括 30 天死亡率、90 天死亡率和切除的淋巴结中位数,在学术医疗机构类型接受治疗的患者中明显更好。
与在社区医疗机构接受治疗的患者相比,在学术医疗机构类型接受治疗的早期 NSCLC 患者的中位总生存期明显更长。对于在学术医疗机构类型接受早期 NSCLC 手术的患者,短期手术质量结果明显更好。